| Name | MK-0773 |
| Description | MK-0773 (PF-05314882) is a selective androgen receptor modulator that binds to AR (IC50: 6.6 nM) for the study of diseases caused by endocrine abnormalities. |
| In vitro | The affinity of MK-0773 for AR across species can be evaluated using COS cells transfected with AR, with respective IC50 values as follows: rat, 0.50 nM; dog, 0.55 nM; rhesus, 0.45 nM; human, 0.65 nM[1]. |
| In vivo | Treatment of OVX rats with MK-0773 (5 mg/kg, 25 mg/kg), 2-FPA, TFM-4AS-1, and DHT for 24 days resulted in a decrease in total cholesterol and high-density lipoprotein by 25-37%[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (4.17 mM), Sonication is recommended. DMSO : 20 mg/mL (41.7 mM), Sonication is recommended.
|
| Keywords | PF05314882 | PF 05314882 | MK-0773 | MK0773 | MK 0773 | AR | AndrogenReceptor | Androgen Receptor |
| Inhibitors Related | Dehydroisoandrosterone 3-acetate | Bicalutamide | 2-Ethylhexyl trans-4-methoxycinnamate | S-23 | Enzalutamide | Octinoxate | Testosterone propionate | Allura Red AC | Sunset Yellow FCF | Ostarine | 2-sec-Butylphenol | Flutamide |
| Related Compound Libraries | Nuclear Receptor Compound Library | Bioactive Compound Library | ReFRAME Related Library | Drug Repurposing Compound Library | Anti-Prostate Cancer Compound Library | Endocrinology-Hormone Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Fluorochemical Library | Bioactive Lipid Compound Library | Transcription Factor-Targeted Compound Library |